tandf: Current Medical Research and Opinion: Table of Contents

tandf: Current Medical Research and Opinion: Table of Contents

Funding for the study and for medical writing assistance was provided by Amgen Inc. Declaration of financial/other relationships S. Shah, L. Raskin, and D. Cohan are employees of and stockholders in Amgen Inc. M. Freeman has served as an advisory board consultant for Bristol-Myers Squibb, Merck, Novartis, and Sanofi-Regeneron. O. Hamid has served as a consultant for Amgen Inc., Novartis, Roche, Bristol-Myers Squibb, Merck; has served on speakers bureau for Amgen Inc., Bristol-Myers Squibb, Genentech, Novartis, Array, and Sanofi-Regeneron; and has received institutional research funding from AstraZeneca, Bristol-Myers Squibb, Celldex, Genentech Roche, Immunocore, Incyte, Merck, Merck Serono, MedImmune, Novartis, Pfizer, Amgen Inc., Cytomx, Iovance, Regeneron, and Polynoma. Peer reviewers on this manuscript have no relevant financial or other relationships to disclose. Author contributions Shweta Shah: Conception and design; analysis and interpretation of the data Leon Raskin: Conception and design; analysis and interpretation of the data David Cohan: Analysis and interpretation of the data Morganna Freeman: Analysis and interpretation of the data Omid Hamid: Analysis and interpretation of the data All authors were involved in the drafting and revision of the manuscript and approve of the final submitted version. All authors agree to be accountable for all aspects of the work. Previous presentation Results of this study have been presented at the American Society of Clinical Oncology Annual Meeting, June 1–5, 2018 in Chicago, IL. Acknowledgements The authors thank Meghan Johnson, PhD (Complete Healthcare Communications, LLC, North Wales, PA, a CHC Group Company), whose work was funded by Amgen Inc., for medical writing assistance in the preparation of this manuscript. Data availability Qualified researchers may request data from Amgen clinical studies. Complete details are available at the following: https://www.amgen.com/science/clinical-trials/clinical-data-transparency-practices/ Article Metrics



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More